Literature DB >> 19755241

First experience with the Impella Recover(R) LP 2.5 micro axial pump in patients with cardiogenic shock or undergoing high-risk revascularisation.

J Dens1, B Meyns, R-D Hilgers, J Maessend, V van Ommen, U Gerckens, E Grube.   

Abstract

AIM: To study the feasibility, safety and efficacy of the Recover(R) LP 2.5 assist device in patients scheduled for high risk off-pump coronary bypass surgery, percutaneous coronary intervention or patients in cardiogenic shock. METHODS AND
RESULTS: 40 patients presenting with cardiogenic shock (n=13) or scheduled for a high risk revascularisation (n=27) were included.36 were selected for safety and feasibility analysis. In 3 patients the pump could not be placed in an adequate position. 5 patients had access related complications. In 9 patients free Hb rose above 80 mg/dl. 3 malfunctions and early device-removal occurred. After device modifications these problems did not recur. CO in the shock group increased significantly: 4.4 l/min+/-1.9 to 4.8 l/min+/-1.2 (p=0.0178).The left ventricular filling pressures decreased in both groups (22 mmHg+/-7.5 to 16 mmHg+/-6 in the shock group, [p=0.0008] and over 6 hours from 14.3 mmHg+/-5.8 to 10 mmHg+/-2.9 in the high-risk revascularisation group,[p=0.0327]).
CONCLUSIONS: The Recover(R) LP 2.5 micro axial pump allows, via percutaneous approach, partial unloading of the left ventricle. The technique is, after design modifications, feasible and safe and results in haemodynamic improvement.

Entities:  

Year:  2006        PMID: 19755241

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  2 in total

1.  Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest.

Authors:  Venkata K Mukku; Qiangjun Cai; Syed Gilani; Ken Fujise; Alejandro Barbagelata
Journal:  Int J Angiol       Date:  2012-09

2.  Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial.

Authors:  Wei Liu; Venkata Kishore Mukku; Syed Gilani; Ken Fujise; Alejandro Barbagelata
Journal:  Int J Angiol       Date:  2013-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.